CA
NZ
UK
AU
IND
US
The company said the designation follows positive Phase 1 clinical signals supporting the drug's activity in this setting, building on earlier interim data disclosed for the broader Varseta-M program in solid tumors.
In this instance, Addex (NASDAQ:ADXN) sold 437,869 ADSs, representing 52.5 million underlying ordinary shares, to raise the $2.8 million in proceeds.
At a median follow-up of more than two years, the study reported no recurrences of colorectal cancer among treated patients, a durability signal that stands out in a tumor subtype where relapse after surgery remains a persistent clinical challenge.
Importantly, the improvements observed at week 24 were sustained through week 52 in both doses tested, indicating that the treatment effect held up over roughly a year of therapy rather than fading over time. Durability data of this kind is often a key consideration …
Following the split, Artelo's (NASDAQ:ARTL) outstanding common stock will be reduced to approximately 547,774 shares. The company has also indicated that outstanding warrants and derivative securities will be proportionately adjusted in line with their respective governing terms, keeping the economic terms of those instruments …
By consolidating existing shares into a smaller number at a proportionally higher price, a reverse split provides a mechanical path back above the minimum threshold, independent of any underlying change in the company'sBusinessor valuation.
By anchoring production domestically, the partnership positions Celularity (NASDAQ:CELU) toSupplyMuseCell-derived material from an established U.S. manufacturing base rather than relying on external or overseas production capacity, a structure that can matter for supply-chain reliability in cell-therapy manufacturing.
With the IND cleared, Adicet Bio (NASDAQ:ACET) has outlined plans to begin Phase 1 enrollment in the fourth quarter of 2026. As an early-stage, first-in-human study, the initial Phase 1 trial will primarily focus on establishing the safety profile and appropriate dosing of ADI-212, …
Summit Therapeutics (NASDAQ:SMMT), a biotechnology company developing the closely watched cancer immunotherapy ivonescimab, rose as maturing survival data and an approaching regulatory decision reinforced investor optimism. For a company whose value is tightly bound to a single high-profile drug, the question is whether the …
Nexalin Technology (NASDAQ:NXL), a small developer of non-invasive neurostimulation devices for mental-health and neurological conditions, plunged after announcing a reverse stock split—an event that often accompanies, and can intensify, weakness in micro-cap shares. The question for investors is whether Nexalin can find a floor …
Please wait processing your request...